HBK Investments’s Astria Therapeutics ATXS Stock Holding History

HBK Investments’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-3,333	Closed	-$192K	–	1165
2018 Q2	$192K	Buy	+3,333	New	+$307K	﹤0.01%	966

Other funds holding ATXS

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

SHI

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Clarus Ventures Cambridge, Massachusetts $425M AUM 26.13% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

HBK Investments's ATXS Position: Q3 2018 in Review

HBK Investments sold out of Astria Therapeutics (ATXS) in Q3 2018, closing a stake of 3,333 shares — an estimated $192K sold.

HBK Investments first reported a position in ATXS in Q2 2018 and held it in 1 quarter. The position peaked at $192K in Q2 2018. 28 funds tracked by Wall St. Rank hold ATXS as of Q3 2018.

HBK Investments reported no remaining Astria Therapeutics position as of Q3 2018 after selling out during the quarter.
HBK Investments sold 3,333 Astria Therapeutics shares in Q3 2018, an estimated $192K.
HBK Investments first reported a position in Astria Therapeutics in Q2 2018 and held it in 1 quarter.
HBK Investments's Astria Therapeutics position peaked at $192K in Q2 2018.
28 funds tracked by Wall St. Rank held Astria Therapeutics as of Q3 2018.

Based on HBK Investments's 13F filing for Q3 2018, filed 14 Nov 2018.